Grand Pharma to commercialize world's first adrenaline nasal spray, Neffy

Grand Pharmaceutical Group Limited announced a product cooperation agreement with Pediatrix Therapeutics Technology (Shanghai) Co. Ltd. to acquire exclusive commercialization rights for Neffy®, the world's first adrenaline nasal spray, in Mainland China, and non-exclusive rights in Hong Kong. Neffy® is designed for emergency treatment of type I allergic reactions in adults and children weighing over 30kg (2mg specification) and children weighing 15-30kg (1mg specification).

The 2mg strength of Neffy® was approved for commercialization in the United States and the European Union in August 2024, with a marketing application submitted to China's NMPA in December 2024. The 1mg specification was approved for commercialization in the United States in March 2025, with both 1mg and 2mg specifications approved for commercialization in Japan in September 2025. Grand Pharma plans to achieve localized production within 24 months after product approval.

This collaboration is expected to enhance accessibility to adrenaline treatment in China, filling a critical gap in out-of-hospital emergency care for severe allergic reactions. The group anticipates that Neffy® will quickly penetrate various out-of-hospital settings, becoming a new growth driver for its cerebro-cardiovascular emergency segment.